Get the Stockscreener App
67.73
2.56%
-1.915
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $67.73, with a volume of 497.21K.
It is down -2.56% in the last 24 hours and up +14.55% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$69.65
Open:
$69.21
24h Volume:
497.21K
Relative Volume:
0.26
Market Cap:
$10.55B
Revenue:
$1.17B
Net Income/Loss:
$150.71M
P/E Ratio:
72.06
EPS:
0.94
Net Cash Flow:
$245.03M
1W Performance:
-1.17%
1M Performance:
+14.55%
6M Performance:
+22.71%
1Y Performance:
-11.76%
1-Day Range:
$67.65
$69.24
1-Week Range:
$66.34
$72.16
52-Week Range:
$46.01
$79.28
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
612-379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
67.74 | 10.85B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.83 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-21-25 | Upgrade | Citigroup | Neutral → Buy |
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jul-09-25 | Initiated | TD Cowen | Buy |
| May-30-25 | Initiated | Wells Fargo | Overweight |
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-18-25 | Initiated | Evercore ISI | Outperform |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-07-23 | Initiated | UBS | Buy |
| Aug-28-23 | Initiated | William Blair | Outperform |
| Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-23-21 | Upgrade | Stifel | Hold → Buy |
| Jan-25-21 | Reiterated | The Benchmark Company | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| May-27-20 | Downgrade | Stifel | Buy → Hold |
| May-14-20 | Initiated | The Benchmark Company | Buy |
| Jan-08-20 | Resumed | Stephens | Overweight |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-02-19 | Upgrade | Janney | Neutral → Buy |
| Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-17-18 | Initiated | Goldman | Neutral |
| Jun-15-18 | Initiated | Argus | Buy |
| Jul-13-17 | Initiated | Wells Fargo | Market Perform |
| Feb-09-17 | Initiated | Citigroup | Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
| Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
Massachusetts Financial Services Co. MA Trims Stake in Bio-Techne Corp $TECH - MarketBeat
Middle East Exosomes Market Research Report 2025-2033: Diagnostic and Therapeutic Adoption, R&D Investment, and Liquid Biopsy Demand Drive Growth - GlobeNewswire Inc.
How to hear Bio-Techne’s Feb. 4 call on Q2 2026 financials - Stock Titan
Bio-Techne Corp $TECH Shares Bought by Stephens Investment Management Group LLC - MarketBeat
Pembroke Management LTD Purchases 37,189 Shares of Bio-Techne Corp $TECH - MarketBeat
R&D Systems™ Luminex® Portfolio - Select Science
Here's what to expect from Bio-Techne's next earnings report - MSN
Bio-Techne Corp (TECH) Stock Analysis: Potential Upside and Analyst Confidence in the Biotech Arena - DirectorsTalk Interviews
Summit Creek Advisors LLC Sells 16,450 Shares of Bio-Techne Corp $TECH - MarketBeat
Conestoga Capital Advisors LLC Reduces Stake in Bio-Techne Corp $TECH - MarketBeat
HB Wealth Management LLC Sells 15,466 Shares of Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors - MSN
(TECH) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Here's What to Expect From Bio-Techne's Next Earnings Report - Yahoo Finance
StreetInsider.comHere's What to Expect From Bio-Techne's Next Earnings Report - FinancialContent
A Look At Bio-Techne (TECH) Valuation After Analyst Downgrade And Softer Cash Flow Concerns - Yahoo Finance
Bio-Techne Corp. stock outperforms competitors on strong trading day - MSN
What technical signals suggest for Bio Techne Corporation stock - ulpravda.ru
What makes Bio Techne Corporation (TE1) stock appealing to growth investorsJuly 2025 News Drivers & Scalable Portfolio Growth Methods - Улправда
How Bio Techne Corporation (TE1) stock reacts to stronger dollar2025 Retail Activity & Safe Entry Momentum Tips - Улправда
Bio-Techne (NASDAQ:TECH) Stock Acquired Rep. April McClain Delaney - MarketBeat
Rep. April McClain Delaney Purchases Shares of Bio-Techne Corp (NASDAQ:TECH) - MarketBeat
Maryland Representative April McClain Delaney Purchased as Much as $135,000 in Bio-Techne Shares - Bitget
Bio-Techne (NASDAQ:TECH) Cut to Hold at Evercore ISI - MarketBeat
Evercore ISI Group downgrades Bio-Techne (TECH) - MSN
TECH: Evercore ISI Downgrades Bio-Techne's Rating and Lowers Pri - GuruFocus
3 Reasons to Avoid TECH and 1 Stock to Buy Instead - Finviz
Should Bio-Techne’s (TECH) Revenue Miss Raise Doubts About Its Scientific Platform’s Commercial Potential? - simplywall.st
Bio-Techne Corp (NASDAQ:TECH) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Fort Washington Investment Advisors Inc. OH Buys 35,165 Shares of Bio-Techne Corp $TECH - MarketBeat
Research Tools & Consumables Stocks Q3 Results: Benchmarking Bio-Techne (NASDAQ:TECH) - Yahoo Finance
Bio-Techne Corp (TECH): Stock Analysis Reveals A 17.64% Potential Upside For Investors - DirectorsTalk Interviews
Bio-Techne Corp (TECH) Stock Price History & Data - Traders Union
Voya Investment Management LLC Has $7.04 Million Holdings in Bio-Techne Corp $TECH - MarketBeat
Assenagon Asset Management S.A. Invests $2.75 Million in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference - Investing News Network
Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
Bio-Techne (TECH): Revisiting Valuation as Recent Gains Contrast a Weak One-Year Shareholder Return - Yahoo Finance
Bio-Techne Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Riverbridge Partners LLC Trims Stock Position in Bio-Techne Corp $TECH - MarketBeat
Will Bio Techne Corporation stock gain from strong economyMarket Rally & Free Low Drawdown Momentum Trade Ideas - Улправда
Why Bio Techne Corporation stock appeals to analystsJuly 2025 Momentum & Capital Protection Trade Alerts - Улправда
Will New 3D Multiomic Workflow and Leo System Expansion Change Bio-Techne's (TECH) Narrative? - simplywall.st
How Bio Techne Corporation stock compares to industry benchmarksJuly 2025 Rallies & Free Weekly Watchlist of Top Performers - DonanımHaber
Bio-Techne (NASDAQ:TECH) Downgraded to Strong Sell Rating by Zacks Research - MarketBeat
Trading Action: Will Bio Techne Corporation stock gain from strong economyMarket Volume Summary & Technical Pattern Based Buy Signals - Улправда
Thrivent Financial for Lutherans Has $11.53 Million Holdings in Bio-Techne Corp $TECH - MarketBeat
Corient Private Wealth LLC Reduces Stake in Bio-Techne Corp $TECH - MarketBeat
Aaron Wealth Advisors LLC Takes $980,000 Position in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):